HCA
CPRX

Harbor Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Harbor Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Hold
616
– – ﹤0.01% 860
2026
Q1 		$15K Buy
616
+359
+140% +$8.55K ﹤0.01% 886
2025
Q4 		$6K Sell
257
-4
-2% -$89 ﹤0.01% 1085
2025
Q3 		$5K Sell
261
-7
-3% -$144 ﹤0.01% 1150
2025
Q2 		$6K Buy
268
+37
+16% +$873 ﹤0.01% 1102
2025
Q1 		$6K Buy
+231
New +$5.2K ﹤0.01% 1113

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbor Capital Advisors's CPRX Position: Q2 2026 in Review

Harbor Capital Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 616 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Harbor Capital Advisors first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Harbor Capital Advisors held 616 shares of Catalyst Pharmaceutical worth $19K as of Q2 2026.
  • Harbor Capital Advisors left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #860 holding.
  • Harbor Capital Advisors first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.